Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-2189 ABBOTT LABORATORIES An Illinois Corporation I.R.S. Employer Identification No. 36-0698440 100 Abbott Park Road Abbott Park, Illinois 60064-6400 Telephone: ( ...

Core Insights - Abbott has entered a groundbreaking agreement to integrate its Libre continuous glucose monitoring (CGM) data into Epic's electronic health record systems in the U.S. This collaboration aims to enhance workflow efficiency for healthcare providers [1][8] Group 1: Integration and Benefits - The integration allows automatic linking of data from users' LibreView accounts to Epic, enabling clinicians to access glucose data seamlessly during patient interactions [2] - This process is designed to help healthcare providers spend less time searching for data and more time on patient care management, ultimately improving patient outcomes [3][4] Group 2: Market Impact - Over 575,000 healthcare providers in the U.S. serving approximately 280 million patients will benefit from this integration, facilitating better collaboration between patients and providers [3] - The integration is expected to simplify diabetes management for nearly 40 million people living with diabetes in the U.S., focusing on reducing administrative burdens [4] Group 3: Company Background - Abbott is recognized as a global leader in healthcare, with a diverse portfolio that includes diagnostics, medical devices, nutritionals, and branded generic medicines, serving people in over 160 countries [6] - The FreeStyle Libre technology has been a significant advancement in diabetes care, currently used by more than 7 million people across over 60 countries [5]

Core Insights - Abbott has announced strong safety and efficacy data from its Volt CE Mark Study for the Volt™ PFA System, demonstrating positive results for patients with atrial fibrillation (AFib) over a 12-month period [1][6] Group 1: Study Findings - The Volt CE Mark Study showed that the Volt PFA System achieved an average of 4.7 therapy applications per vein, which is fewer than competitive PFA systems [1] - After 12 months, 83.5% of patients with paroxysmal atrial fibrillation (PAF) and 58.1% of patients with persistent AFib (PersAF) remained free from atrial arrhythmia, indicating one of the lowest recurrence rates in long-term PFA studies [7] - Quality of life (QoL) scores improved significantly from 64.1 to 88.1 after 12 months of treatment [7] Group 2: Safety Profile - The Volt PFA System demonstrated an excellent safety profile, with only 2.7% of patients experiencing a primary safety endpoint event, and no cases of hemolysis, coronary artery spasm, pulmonary vein stenosis, acute kidney injury, or phrenic nerve injury reported [7] - The study confirmed that the Volt PFA System can effectively treat both PAF and PersAF patients, enhancing procedural flexibility with options for light sedation or general anesthesia [4][8] Group 3: Study Design - The Volt CE Mark Study is a prospective, single-arm, non-randomized, multicenter study that enrolled 150 patients across 11 sites in Europe, focusing on symptomatic, recurrent, drug-refractory PAF and PersAF [8]

Abbott Laboratories (ABT) has recorded a 15% rise in its share price year to date. Despite the company reporting a solid first-quarter 2025 earnings beat last week, external pressure, particularly the ongoing tariff war, has dampened investors' enthusiasm and capped further market gains. Let's delve deeper.Since its earnings release on April 16, shares of Abbott have edged down 0.2%, underperforming the industry as well as the S&P 500’s gain of 2%. The broader Medical sector collectively gained 1% during th ...

Core Insights - The article emphasizes the importance of conducting personal in-depth research and due diligence before making investment decisions, highlighting the inherent risks involved in trading [3]. Company and Industry Summary - The analysis is intended solely for informational purposes and should not be interpreted as professional investment advice [3][4]. - There is a clear disclaimer regarding the lack of any stock or derivative positions in the companies mentioned, indicating a neutral stance from the analyst [2].

Abbott Laboratories ABT reported better-than-expected first-quarter adjusted EPS results on Wednesday.Abbott Laboratories reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management guidance of $1.05-$1.09."Once again, Abbott's diversified business model delivered top-tier sales and EPS growth," said Robert Ford, chairman and CEO of Abbott. ...

Core Viewpoint - Abbott Laboratories (NYSE: ABT) has been assigned a "Strong Buy" rating due to its robust growth in the medical device and pharmaceutical markets, leading to significant stock price outperformance compared to the overall market index [1]. Company Performance - Since the "Strong Buy" rating was assigned in October 2024, Abbott's stock price has significantly outperformed the overall market index, indicating strong investor confidence and market performance [1]. Market Position - Abbott Laboratories is experiencing strong growth in both the medical device and pharmaceutical sectors, which are key drivers of its stock performance and overall business success [1].

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Insights - Abbott reported $10.36 billion in revenue for Q1 2025, a 4% year-over-year increase, with an EPS of $1.09 compared to $0.98 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $10.42 billion, resulting in a surprise of -0.56%, while the EPS exceeded expectations by 1.87% [1] Financial Performance Metrics - Net sales in Nutrition - International reached $1.19 billion, matching the average estimate, with a year-over-year change of +0.1% [4] - Net sales in Nutrition - U.S. were $955 million, surpassing the estimated $925.35 million, reflecting an 8.8% increase year-over-year [4] - Net sales in Diagnostics - U.S. totaled $871 million, below the estimated $927.13 million, showing a year-over-year decline of -6.4% [4] - Net sales in Diagnostics - International were $1.18 billion, compared to the estimated $1.28 billion, indicating a -7.8% year-over-year change [4] - Total net sales in Nutrition amounted to $2.15 billion, exceeding the estimated $2.12 billion, with a +3.8% change year-over-year [4] - Medical Devices - Diabetes Care generated $1.83 billion, slightly above the estimated $1.82 billion, marking a +16.4% year-over-year increase [4] - Total net sales in Diagnostics were $2.05 billion, below the estimated $2.19 billion, reflecting a -7.2% year-over-year change [4] - Established Pharmaceuticals net sales reached $1.26 billion, slightly above the estimated $1.23 billion, with a +2.8% year-over-year change [4] - Medical Devices - Vascular total sales were $710 million, exceeding the estimated $704.85 million, with a +3.1% year-over-year change [4] - Medical Devices - Neuromodulation total sales were $228 million, slightly below the estimated $235.53 million, with a +0.9% year-over-year change [4] - Medical Devices - Structural Heart total sales were $577 million, below the estimated $592.77 million, reflecting a +12% year-over-year change [4] - Medical Devices - Heart Failure total sales were $339 million, surpassing the estimated $325.77 million, with an +11.2% year-over-year change [4] Stock Performance - Abbott's shares returned -0.1% over the past month, compared to the Zacks S&P 500 composite's -4.2% change, indicating relative stability [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Viewpoint - Abbott reported quarterly earnings of $1.09 per share, exceeding the Zacks Consensus Estimate of $1.07 per share, and showing an increase from $0.98 per share a year ago, indicating a positive earnings surprise of 1.87% [1][2] Financial Performance - The company posted revenues of $10.36 billion for the quarter ended March 2025, which was below the Zacks Consensus Estimate by 0.56%, but up from $9.96 billion year-over-year [2] - Over the last four quarters, Abbott has surpassed consensus EPS estimates three times and topped revenue estimates twice [2] Stock Performance - Abbott shares have increased approximately 11.6% since the beginning of the year, contrasting with the S&P 500's decline of -8.3% [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $1.25 for the coming quarter and $5.15 for the current fiscal year, alongside expected revenues of $11 billion and $44.42 billion respectively [7] - The estimate revisions trend for Abbott is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Products industry, to which Abbott belongs, is currently ranked in the bottom 25% of over 250 Zacks industries, indicating potential challenges ahead [8]